Organ & Kidney Transplant Essentials

Introduction & Rationale

  • Organ transplantation = removal of a healthy organ from donor → implantation into recipient with end-organ failure

  • Provides “second chance” at life; kidney graft can add 10\text{–}20\,\text{yr}

Kidney Basics

  • Major roles: filtration of metabolic waste (urea), electrolyte & acid–base balance, BP regulation (RAAS), endocrine (EPO, vitamin D activation)

  • Complete renal failure → death within days without support

Kidney Failure & Dialysis

  • Leading causes: diabetic nephropathy & hypertensive nephrosclerosis (≈80\% of ESRD)

  • Dialysis (1943 Kolff): extracorporeal or peritoneal; replaces filtration only
    • Burden: 3\text{–}5\,h sessions, multiple wk; PD nightly
    • 5\,\text{yr} dialysis survival ≈30\%

Why Transplant > Dialysis

  • Restores ALL kidney functions

  • Far superior survival & quality of life

Historical Milestones

  • 1910 Alexis Carrel: vascular anastomosis (Carrel patch)

  • 1933 Voronoy: first human attempt (failed)

  • 1947 Kuss et al.: temporary “bridge” graft

  • 1954 Murray: first successful long-term graft (identical twins) → Nobel Prize

Surgical Overview (Renal)

  1. Donor nephrectomy, rapid cold perfusion (ice + preservation solution)

  2. Implantation in iliac fossa; anastomose renal artery/vein to external iliac vessels; attach ureter to bladder

  3. Acceptable cold ischemia: <12\,h on ice; \le 72\,h on machine perfusion

Immunology Essentials

  • Innate vs Adaptive immunity

  • Adaptive key cells: T cells (helper, cytotoxic), B cells → antibodies

  • Major histocompatibility complex (MHC) = human leukocyte antigen (HLA) presents antigen to T cells → main target in rejection

  • Rejection types
    • Hyperacute (minutes): pre-formed ABO/HLA antibodies
    • Acute (days–months): T/B cell response to mismatched HLA
    • Chronic (mo–yrs): gradual fibrosis/vasculopathy

Donor–Recipient Matching

  1. ABO blood typing – prevents hyperacute rejection

  2. HLA tissue typing – goal: maximize matches (HLA-A, -B, -DR most critical)

  3. Crossmatch – mix donor cells + recipient serum; look for cytotoxicity/agglutination (must be negative)

Immunosuppression Strategies

  • Induction (peri-op): anti-thymocyte globulin, IL-2R blockers

  • Maintenance: calcineurin inhibitors (tacrolimus/cyclosporine), antiproliferatives (mycophenolate), steroids ± mTOR inhibitors

  • Adjuncts: plasmapheresis, IVIG, splenectomy, radiation (rare)

  • Balance: prevent rejection yet preserve infection/cancer defense

Candidate Considerations

  • Anatomy: adequate vasculature & venous access

  • Comorbidities: cardiovascular fitness, infection, cancer

  • Immunologic status: prior transplants, sensitization (PRA)

  • Frailty/age → ability to tolerate major surgery

Key Numbers & Facts

  • Cold ischemia limits: kidney <12\,h (static ice) / \le 72\,h (pumped)

  • Dialysis 5\,\text{yr} survival \approx 30\% vs graft >80\%

  • Universal donor blood = O^{\text{–}}; universal recipient = AB^{\text{+}}

Core Takeaways

  • Transplantation cures ESRD far better than dialysis but demands precise surgery, HLA/ABO matching & lifelong immunosuppression.

  • Understanding innate/adaptive immunity & HLA biology underpins modern success rates.

  • Ongoing advances: machine preservation, targeted immunotherapy, xenotransplant & regenerative medicine.